Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 7/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830504 | 0.79 | PPARD (0.43) | PPARDTP53GAAMAPK1SMN1; SMN2 | |
| SCHEMBL27735351 | 0.77 | PPARD (0.41) | PPARDTP53GAAMAPK1SMN1; SMN2 | |
| SCHEMBL14143831 | 0.74 | PPARD (0.51) | PPARDTP53GAAMAPK1SMN1; SMN2 | |
| SCHEMBL2829273 | 0.74 | PPARD (0.40) | PPARDTP53GAAMAPK1SMN1; SMN2 | |
| SCHEMBL13170771 | 0.73 | PPARD (0.45) | PPARDTP53GAAMAPK1SMN1; SMN2 | |
| SCHEMBL28067564 | 0.72 | PPARD (0.49) | PPARDTP53GAASMN1; SMN2PDE4A | |
| SCHEMBL27687788 | 0.72 | MAPK1 (0.38) | PPARDTP53GAAMAPK1SMN1; SMN2 | |
| SCHEMBL13170772 | 0.71 | PPARD (0.44) | PPARDTP53GAAMAPK1SMN1; SMN2 | |
| SCHEMBL20969707 | 0.71 | KARS1 (0.65) | PPARDTP53GAAMAPK1SMN1; SMN2 | |
| SCHEMBL24046581 | 0.70 | INSR (0.64) | PPARDTP53MAPK1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227834-A1 | DERIVATIVES OF 2-AMINOTHIAZOLES AND 2-AMINO-OXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| US-20080227834-A1 | DERIVATIVES OF 2-AMINOTHIAZOLES AND 2-AMINO-OXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227834-A1 | DERIVATIVES OF 2-AMINOTHIAZOLES AND 2-AMINO-OXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | PPARA, PPARD, PPARG | PPARD 2/4885TP53 4057/4885GAA 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.